Details
Stereochemistry | ACHIRAL |
Molecular Formula | C25H32ClN5O2.ClH |
Molecular Weight | 506.468 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCC1=NN(CCCN2CCN(CC2)C3=CC(Cl)=CC=C3)C(=O)N1CCOC4=CC=CC=C4
InChI
InChIKey=DYCKFEBIOUQECE-UHFFFAOYSA-N
InChI=1S/C25H32ClN5O2.ClH/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22;/h3-6,8-11,20H,2,7,12-19H2,1H3;1H
DescriptionSources: http://www.drugbank.ca/drugs/DB01149Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/nefazodone.html
Sources: http://www.drugbank.ca/drugs/DB01149
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/nefazodone.html
Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. Within the serotonergic system, nefazodone acts as an antagonist at type 2 serotonin (5-HT2) post-synaptic receptors and, like fluoxetine-type antidepressants, inhibits pre-synaptic serotonin (5-HT) reuptake. These mechanisms increase the amount of serotonin available to interact with 5-HT receptors. Within the noradrenergic system, nefazodone inhibits norepinephrine uptake minimally. Nefazodone also antagonizes alpha(1)-adrenergic receptors, producing sedation, muscle relaxation, and a variety of cardiovascular effects. Nefazodone's affinity for benzodiazepine, cholinergic, dopaminergic, histaminic, and beta or alpha(2)-adrenergic receptors is not significant.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2274630
Curator's Comment: antidepressant
Originator
Sources: http://adisinsight.springer.com/drugs/800000656
Curator's Comment: # Bristol-Myers Squibb
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL224 Sources: http://www.drugbank.ca/drugs/DB01149 |
5.8 nM [Ki] | ||
Target ID: CHEMBL228 Sources: http://www.drugbank.ca/drugs/DB01149 |
290.0 nM [Ki] | ||
Target ID: CHEMBL2094251 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9400006 |
5.5 nM [Ki] | ||
Target ID: CHEMBL2095158 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9400006 |
84.0 nM [Ki] | ||
Target ID: CHEMBL214 Sources: http://www.drugbank.ca/drugs/DB01149 |
52.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NEFAZODONE HYDROCHLORIDE Approved UseNefazodone hydrochloride tablets are indicated for the treatment of depression. When deciding among the alternative treatments available for this condition, the prescriber should consider the risk of hepatic failure associated with Nefazodone hydrochloride treatment. In many cases, this would lead to the conclusion that other drugs should be tried first. Launch Date1.06358401E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1588 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8951188/ |
200 mg 2 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
880 μg/L |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
415 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8951188/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
276 μg/L |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6378 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8951188/ |
200 mg 2 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
3213 μg × h/L |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1220 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8951188/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
787 μg × h/L |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7 h |
100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8951188/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
5.7 h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
NEFAZODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg single, oral Highest studied dose |
unhealthy, adult n = 12 Health Status: unhealthy Condition: hepatic cirrhosis Age Group: adult Sex: unknown Population Size: 12 Sources: |
Other AEs: Nausea and vomiting... |
200 mg single, oral Highest studied dose |
unhealthy, adult n = 12 Health Status: unhealthy Condition: renal impairment Age Group: adult Sex: unknown Population Size: 12 Sources: |
Other AEs: Nausea and vomiting... |
430 mg 1 times / day steady, oral (mean) Highest studied dose Dose: 430 mg, 1 times / day Route: oral Route: steady Dose: 430 mg, 1 times / day Sources: |
unhealthy, adult n = 19 Health Status: unhealthy Condition: Posttraumatic stress disorder Age Group: adult Sex: M Population Size: 19 Sources: |
Other AEs: Headaches, Dry mouth... Other AEs: Headaches (53%) Sources: Dry mouth (42%) Diarrhea (42%) |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Other AEs: Dry mouth, Nausea... Other AEs: Dry mouth (25%) Sources: Page: Table 1Nausea (22%) Dizziness (17%) Constipation (14%) Asthenia (11%) Light headedness (10%) Blurred vision (9%) Confusion (7%) Abnormal vision (7%) |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 2 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 2 |
Other AEs: Somnolence... |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 565 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 565 Sources: Page: Table 1 |
Disc. AE: Nausea, Headache... AEs leading to discontinuation/dose reduction: Nausea (3.5%) Sources: Page: Table 1Headache (2.9%) Dizziness (1.9%) Somnolence (1.5%) Insomnia (1.5%) Asthenia (1.3%) Agitation (1.2%) |
200 mg single, oral Highest studied dose |
healthy, elderly n = 12 Health Status: healthy Age Group: elderly Sex: unknown Population Size: 12 Sources: |
Other AEs: Nausea and vomiting... |
200 mg single, oral Highest studied dose |
healthy, younger n = 12 Health Status: healthy Age Group: younger Sex: unknown Population Size: 12 Sources: |
Other AEs: Nausea and vomiting... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Nausea and vomiting | 200 mg single, oral Highest studied dose |
unhealthy, adult n = 12 Health Status: unhealthy Condition: hepatic cirrhosis Age Group: adult Sex: unknown Population Size: 12 Sources: |
|
Nausea and vomiting | 200 mg single, oral Highest studied dose |
unhealthy, adult n = 12 Health Status: unhealthy Condition: renal impairment Age Group: adult Sex: unknown Population Size: 12 Sources: |
|
Diarrhea | 42% | 430 mg 1 times / day steady, oral (mean) Highest studied dose Dose: 430 mg, 1 times / day Route: oral Route: steady Dose: 430 mg, 1 times / day Sources: |
unhealthy, adult n = 19 Health Status: unhealthy Condition: Posttraumatic stress disorder Age Group: adult Sex: M Population Size: 19 Sources: |
Dry mouth | 42% | 430 mg 1 times / day steady, oral (mean) Highest studied dose Dose: 430 mg, 1 times / day Route: oral Route: steady Dose: 430 mg, 1 times / day Sources: |
unhealthy, adult n = 19 Health Status: unhealthy Condition: Posttraumatic stress disorder Age Group: adult Sex: M Population Size: 19 Sources: |
Headaches | 53% | 430 mg 1 times / day steady, oral (mean) Highest studied dose Dose: 430 mg, 1 times / day Route: oral Route: steady Dose: 430 mg, 1 times / day Sources: |
unhealthy, adult n = 19 Health Status: unhealthy Condition: Posttraumatic stress disorder Age Group: adult Sex: M Population Size: 19 Sources: |
Light headedness | 10% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Asthenia | 11% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Constipation | 14% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Dizziness | 17% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Nausea | 22% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Dry mouth | 25% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Abnormal vision | 7% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Confusion | 7% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Blurred vision | 9% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 1 |
Somnolence | 25% | 600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 2 |
unhealthy, adult n = 394 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 394 Sources: Page: Table 2 |
Agitation | 1.2% Disc. AE |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 565 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 565 Sources: Page: Table 1 |
Asthenia | 1.3% Disc. AE |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 565 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 565 Sources: Page: Table 1 |
Insomnia | 1.5% Disc. AE |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 565 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 565 Sources: Page: Table 1 |
Somnolence | 1.5% Disc. AE |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 565 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 565 Sources: Page: Table 1 |
Dizziness | 1.9% Disc. AE |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 565 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 565 Sources: Page: Table 1 |
Headache | 2.9% Disc. AE |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 565 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 565 Sources: Page: Table 1 |
Nausea | 3.5% Disc. AE |
600 mg 1 times / day steady, oral (max) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: steady Dose: 600 mg, 1 times / day Sources: Page: Table 1 |
unhealthy, adult n = 565 Health Status: unhealthy Condition: major depression Age Group: adult Sex: unknown Population Size: 565 Sources: Page: Table 1 |
Nausea and vomiting | 200 mg single, oral Highest studied dose |
healthy, elderly n = 12 Health Status: healthy Age Group: elderly Sex: unknown Population Size: 12 Sources: |
|
Nausea and vomiting | 200 mg single, oral Highest studied dose |
healthy, younger n = 12 Health Status: healthy Age Group: younger Sex: unknown Population Size: 12 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
weak | ||||
yes [IC50 4.7 uM] | ||||
yes [IC50 9 uM] | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Interactions between herbal medicines and prescribed drugs: a systematic review. | 2001 |
|
Third-generation antidepressants: do they offer advantages over the SSRIs? | 2001 |
|
Long-term treatment of recurrent and chronic depression. | 2001 |
|
Pharmacokinetically induced benzodiazepine withdrawal. | 2001 Autumn |
|
A probable interaction between a very low-dose oral contraceptive and the antidepressant nefazodone: a case report. | 2001 Dec |
|
Possible interaction of zopiclone and nefazodone. | 2001 Nov |
|
Pharmacotherapy for post-traumatic stress disorder: a comprehensive review. | 2001 Oct |
|
An open-label, 12-week clinical and sleep EEG study of nefazodone in chronic combat-related posttraumatic stress disorder. | 2001 Oct |
|
[Pharmacotherapeutical approaches to insomnia patients with cardiac diseases and after heart transplantation]. | 2001 Oct |
|
Charleston Antidepressant Drug Interactions Surveillance Program (CADISP). | 2001 Spring |
|
Nefazodone in the treatment of elderly patients with depressive disorders: a prospective, observational study. | 2002 |
|
Clinically significant drug interactions with antidepressants in the elderly. | 2002 |
|
Mood disorders in patients with epilepsy: epidemiology and management. | 2002 |
|
Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist. | 2002 |
|
Cost savings with nefazodone in treating depression. | 2002 |
|
Pharmacology of antidepressants: focus on nefazodone. | 2002 |
|
Prevalence of sexual dysfunction among newer antidepressants. | 2002 Apr |
|
Serzone. Beware of dangerous liver problems. | 2002 Apr |
|
Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents. | 2002 Apr |
|
Human CYP3A4 and the metabolism of nefazodone and hydroxynefazodone by human liver microsomes and heterologously expressed enzymes. | 2002 Apr |
|
Nefazodone and liver damage. | 2002 Aug |
|
Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. | 2002 Aug |
|
Differential effects of amitriptyline, nefazodone and paroxetine on performance and brain indices of visual selective attention and working memory. | 2002 Aug |
|
An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding. | 2002 Dec 30 |
|
Hepatotoxicity associated with the new antidepressants. | 2002 Feb |
|
Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. | 2002 Jan 15 |
|
[Acute liver failure in nefazodone therapy? A case report]. | 2002 Jul |
|
An open-label clinical trial of nefazodone in hypochondriasis. | 2002 Jul-Aug |
|
Optimizing antidepressant treatment: efficacy and tolerability. | 2002 Jun |
|
Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. | 2002 Jun |
|
Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. | 2002 Jun |
|
New antidepressants in the treatment of neuropathic pain. A review. | 2002 Mar |
|
From the Food and Drug Administration. | 2002 Mar 6 |
|
Evaluating changes in sexual functioning in depressed patients: sensitivity to change of the CSFQ. | 2002 Mar-Apr |
|
Nefazodone treatment of dysthymic disorder an open, long-term, prospective pilot study. | 2002 May |
|
Pharmacological interactions of statins. | 2002 May |
|
Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. | 2002 May |
|
Hepatic adverse reactions associated with nefazodone. | 2002 May |
|
Loratadine/nefazodone interaction. | 2002 May |
|
Effects of smoked marijuana in healthy and HIV + marijuana smokers. | 2002 Nov |
|
Combination therapy in the treatment of major depressive disorder complicated by fibromyalgia and menopause. | 2002 Nov-Dec |
|
Nefazodone alters NPY immunostaining in rat arcuate-paraventricular projection without changes in food intake and body weight. | 2002 Oct |
|
Antidepressant-induced sexual dysfunction. | 2002 Oct |
|
Effects of nefazodone on voluntary ethanol consumption induced by isolation stress in young and aged rats. | 2002 Oct |
|
[Pharmacological justification for the use of new antidepressant drugs]. | 2002 Sep |
|
Reversible penile priapism associated with nefazodone. | 2002 Sep |
|
Rhabdomyolysis with simvastatin and nefazodone. | 2002 Sep |
|
Nefazodone and cyp450 3a4 interactions with cyclosporine and tacrolimus1. | 2002 Sep 15 |
|
Enhanced resolution triple-quadrupole mass spectrometry for fast quantitative bioanalysis using liquid chromatography/tandem mass spectrometry: investigations of parameters that affect ruggedness. | 2003 |
|
Nefazodone decreases anxiety during marijuana withdrawal in humans. | 2003 Jan |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/nefazodone.html
Initial dose: 200 mg orally per day in two divided doses
Maintenance dose: 300 to 600 mg orally per day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20606004
In vitro biliary excretion of micafungin in humans and rats was reduced by 75% in the presence of the bile salt export pump (BSEP) inhibitor nefazodone (25 uM)
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C265
Created by
admin on Wed Jul 05 23:53:44 UTC 2023 , Edited by admin on Wed Jul 05 23:53:44 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1457902
Created by
admin on Wed Jul 05 23:53:44 UTC 2023 , Edited by admin on Wed Jul 05 23:53:44 UTC 2023
|
PRIMARY | |||
|
SUB03399MIG
Created by
admin on Wed Jul 05 23:53:44 UTC 2023 , Edited by admin on Wed Jul 05 23:53:44 UTC 2023
|
PRIMARY | |||
|
DBSALT000406
Created by
admin on Wed Jul 05 23:53:44 UTC 2023 , Edited by admin on Wed Jul 05 23:53:44 UTC 2023
|
PRIMARY | |||
|
760344
Created by
admin on Wed Jul 05 23:53:44 UTC 2023 , Edited by admin on Wed Jul 05 23:53:44 UTC 2023
|
PRIMARY | |||
|
82752-99-6
Created by
admin on Wed Jul 05 23:53:44 UTC 2023 , Edited by admin on Wed Jul 05 23:53:44 UTC 2023
|
PRIMARY | |||
|
DTXSID8046088
Created by
admin on Wed Jul 05 23:53:44 UTC 2023 , Edited by admin on Wed Jul 05 23:53:44 UTC 2023
|
PRIMARY | |||
|
CHEMBL623
Created by
admin on Wed Jul 05 23:53:44 UTC 2023 , Edited by admin on Wed Jul 05 23:53:44 UTC 2023
|
PRIMARY | |||
|
236082
Created by
admin on Wed Jul 05 23:53:44 UTC 2023 , Edited by admin on Wed Jul 05 23:53:44 UTC 2023
|
PRIMARY | RxNorm | ||
|
27X63J94GR
Created by
admin on Wed Jul 05 23:53:44 UTC 2023 , Edited by admin on Wed Jul 05 23:53:44 UTC 2023
|
PRIMARY | |||
|
C29283
Created by
admin on Wed Jul 05 23:53:44 UTC 2023 , Edited by admin on Wed Jul 05 23:53:44 UTC 2023
|
PRIMARY | |||
|
100000085692
Created by
admin on Wed Jul 05 23:53:44 UTC 2023 , Edited by admin on Wed Jul 05 23:53:44 UTC 2023
|
PRIMARY | |||
|
27X63J94GR
Created by
admin on Wed Jul 05 23:53:44 UTC 2023 , Edited by admin on Wed Jul 05 23:53:44 UTC 2023
|
PRIMARY | |||
|
7495
Created by
admin on Wed Jul 05 23:53:44 UTC 2023 , Edited by admin on Wed Jul 05 23:53:44 UTC 2023
|
PRIMARY | |||
|
M7793
Created by
admin on Wed Jul 05 23:53:44 UTC 2023 , Edited by admin on Wed Jul 05 23:53:44 UTC 2023
|
PRIMARY | Merck Index | ||
|
54911
Created by
admin on Wed Jul 05 23:53:44 UTC 2023 , Edited by admin on Wed Jul 05 23:53:44 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD